AU2139388A - Glycosaminoglycane for the treatment of diabetic microangiopathy - Google Patents

Glycosaminoglycane for the treatment of diabetic microangiopathy

Info

Publication number
AU2139388A
AU2139388A AU21393/88A AU2139388A AU2139388A AU 2139388 A AU2139388 A AU 2139388A AU 21393/88 A AU21393/88 A AU 21393/88A AU 2139388 A AU2139388 A AU 2139388A AU 2139388 A AU2139388 A AU 2139388A
Authority
AU
Australia
Prior art keywords
diabetic microangiopathy
glycosaminoglycane
treatment
prophylaxy
glycosaminoglycanes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21393/88A
Inventor
Roland Reiner
Helgard Reiner-Struschka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2139388A publication Critical patent/AU2139388A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

It has been discovered that glycosaminoglycanes such as chondroitin sulphate are highly effective as therapeutic and prophylactic agents against diabetic microangiopathy (retinopathy, nephropathy and other manifestations related to capillary pathologies). Glycosaminoglycanes may be used as oral, parenteral or topic preparations for the therapy and prophylaxy of diabetic microangiopathy. Because of its effectiveness when orally administered and of its remarkable compatibility, the oral administration of chondroitin sulphate is particularly advantageous, since this compound is specially suitable for the long term therapy and prophylaxy of diabetic microangiopathy.
AU21393/88A 1988-06-27 1988-08-18 Glycosaminoglycane for the treatment of diabetic microangiopathy Abandoned AU2139388A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH244288 1988-06-27
CH2442/88 1988-06-27

Publications (1)

Publication Number Publication Date
AU2139388A true AU2139388A (en) 1990-01-23

Family

ID=4233917

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21393/88A Abandoned AU2139388A (en) 1988-06-27 1988-08-18 Glycosaminoglycane for the treatment of diabetic microangiopathy

Country Status (6)

Country Link
EP (1) EP0380501B1 (en)
JP (1) JPH03500168A (en)
AT (1) ATE81462T1 (en)
AU (1) AU2139388A (en)
DE (1) DE3875349D1 (en)
WO (1) WO1990000058A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245907B (en) * 1991-05-17 1994-10-25 Alfa Wassermann Spa USE OF GLYCOSAMINOGLICANS IN THE TREATMENT OF DIABETIC NEPHROPATHY AND DIABETIC NEUROPATHY.
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
IT1270095B (en) * 1994-09-28 1997-04-28 Ibsa Inst Biochimique Sa THERAPEUTIC COMPOSITIONS OF CHONDROITIN SULPHATE IN THE FORM OF ORAL ADMINISTRABLE GEL
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
WO1999004801A1 (en) * 1997-07-28 1999-02-04 Rijks Universiteit Leiden Use of sulfated glycosaminoglycans for treating of retinopathy
DE19747195A1 (en) * 1997-10-24 1999-04-29 Knoll Ag Compositions for treating diabetic retinopathy
US8003782B1 (en) 1999-02-01 2011-08-23 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
JP4554910B2 (en) * 2002-11-01 2010-09-29 生化学工業株式会社 Hypoglycemic agent
JP2009234916A (en) * 2006-07-24 2009-10-15 Stelic Institute Of Regenerative Medicine Insulin resistance reducer based on chondroitin sulfate proteoglycan accumulation regulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544136B2 (en) * 1986-05-23 1996-10-16 第一製薬株式会社 Angiogenesis inhibitor and antitumor agent containing sulfated polysaccharide DS4152
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
JP2667441B2 (en) * 1988-05-18 1997-10-27 生化学工業株式会社 Vascular endothelial cell growth inhibitor

Also Published As

Publication number Publication date
WO1990000058A1 (en) 1990-01-11
JPH03500168A (en) 1991-01-17
DE3875349D1 (en) 1992-11-19
EP0380501A1 (en) 1990-08-08
EP0380501B1 (en) 1992-10-14
ATE81462T1 (en) 1992-10-15

Similar Documents

Publication Publication Date Title
BR0012136A (en) Highly selective norepinephrine reabsorption inhibitors and methods of using them
IT1252868B (en) ANTI-PHALALGIC PHARMACEUTICAL COMPOSITION FOR ENDONASAL ADMINISTRATION, PROCEDURE TO PREPARE IT AND ITS THERAPEUTIC USE
AU6444786A (en) The use of 2-amino-3-benzoylbenzeneacetic acids and derivatives in pharmaceutical preparations
MY119403A (en) Novel compounds with analgesic effect.
IE893840L (en) Use of acetyl d-carnitines for treating glaucoma
SG54210A1 (en) Oral composition for the treatment of bowel inflammatory bowel diseases
UA41355C2 (en) Agent for treating neuro-aids
ES2140565T3 (en) NEW DERIVATIVES OF PIRAZINE-CARBOXAMIDE, ITS PREPARATION AND ITS USE IN MEDICINES.
ATE282418T1 (en) ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
AU2139388A (en) Glycosaminoglycane for the treatment of diabetic microangiopathy
EP0270690A4 (en) Drug for treatment and prophylaxis of kidney and liver diseases.
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
AU2861389A (en) Disubstituted pyridines
PH27446A (en) Compound with gastric acid inhibitory effect
AU1956092A (en) Pharmaceutical agent for treatment of withdrawal symptoms
CA2095352A1 (en) Compositions containing psyllium
ES2090167T3 (en) TOPIC USE OF GLYCOSAMINOGLYCANS IN THE PREVENTION AND TREATMENT OF DISEASES AFFECTING THE CERVICAL VAGINAL TRACT.
YU13599A (en) Use of pharmaceutical composition for preparation of medicament in a gel form
AU4040195A (en) Topical composition containing penciclovir
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
DE69709891T2 (en) COMPOSITION CONTAINING CHITOSAN
NO953003L (en) Use of ifenprodil and its diastereoisomers for the preparation of medical preparations
IT1243368B (en) Use of bendazac and of its pharmaceutically acceptable salts
ES2083503T3 (en) AN IMIDAZOBENZODIAZEPINA FOR THE TREATMENT OF SLEEP DISORDERS.